Stem Cell Therapy for Necrotizing Enterocolitis

Necrotizing enterocolitis (NEC) is a devastating intestinal disease of premature infants, and one of the few serious neonatal conditions with no approved medical therapy at all — treatment today means bowel rest, antibiotics, and, in severe cases, emergency surgery. This article covers why researchers are pursuing mesenchymal stem cells (MSCs) as a way to protect and repair the newborn gut, what the animal and early human evidence actually shows, and why this remains a preclinical, investigational approach rather than something available in hospitals today.

Overview

NEC affects roughly 5–12% of very-low-birth-weight infants and carries a mortality rate as high as 30–50% in its most severe, surgical form. Survivors often face short bowel syndrome, feeding problems, and neurodevelopmental impairment. Because no drug currently targets the underlying gut-barrier breakdown and inflammation that drive NEC, it has become a priority target for regenerative, cell-based approaches.

How It's Thought to Work

Researchers believe MSCs — sourced from bone marrow, umbilical cord tissue, placenta, or amniotic fluid — could help by releasing signaling proteins that calm the excessive inflammatory response in the newborn intestine, strengthen the gut's protective barrier, reduce cell death in the intestinal lining, and support tissue repair. Rather than replacing damaged bowel, the cells appear to act as a kind of biological first-aid signal to the injured tissue, which is why most current research delivers them early, before or alongside the worst intestinal injury.

What the Evidence Shows

The strongest evidence remains preclinical, but it is genuinely substantial and consistent. A 2020 systematic review and meta-analysis in Frontiers in Pediatrics pooled nine animal studies (mostly rat models) testing MSCs, amniotic fluid stem cells, and related cell products against experimental NEC. The results were striking: treated animals had significantly lower odds of developing any-grade NEC (odds ratio 0.22) and severe grade 3–4 disease (odds ratio 0.28), and dramatically better survival — more than doubled at 4 days (odds ratio 2.89) and nearly quadrupled at 7 days (odds ratio 3.96) compared with untreated animals. Treated animals also showed reduced intestinal permeability and improved gut motility. A 2024 review in Pediatric Research on translating these therapies to the neonatal intensive care unit called the mechanistic case "compelling" and noted that similar stem cell approaches have already passed Phase I human safety trials in a related premature-infant lung disease, bronchopulmonary dysplasia — precedent researchers hope to build on for NEC.

Human evidence, by contrast, is limited to a single published case. In 2021, clinicians reported in the Journal of Neonatal Nursing the first known use of MSC transplantation in an infant with NEC: a baby born at 32 weeks who developed severe, surgery-requiring disease and received umbilical cord-derived MSCs as a compassionate, experimental intervention, with a reported satisfactory outcome. The authors were careful to frame this as one case, not proof of efficacy.

Reviewers are candid about what's missing: no infant with NEC has yet been enrolled in a controlled clinical trial of stem cell therapy, and the 2024 Pediatric Research review attributes this less to any doubt about the biology than to practical hurdles — the rarity and suddenness of severe NEC, the difficulty of trial design in critically ill newborns, and the need for standardized cell-manufacturing protocols. No stem cell product is FDA-approved for NEC, or for any other neonatal intestinal disease, and researchers have proposed structured frameworks to move carefully from case reports toward formal Phase I/II feasibility trials.

Who Might Be a Candidate

There is currently no approved or generally available MSC treatment for NEC — this list describes who future trials are expected to target, not an option parents can pursue today:

• Premature infants with confirmed or strongly suspected NEC, particularly surgical-stage (Bell stage III) disease
• Infants at high risk of short bowel syndrome or recurrent complications after NEC surgery
• Cases considered for treatment only within an approved research protocol or, rarely, as compassionate use under direct neonatology and ethics oversight
• Families who have discussed the experimental nature of any such option in detail with their infant's care team

Bottom Line

Necrotizing enterocolitis remains a disease without an approved medicine, and the preclinical case for MSC therapy is unusually strong for such an early-stage field — multiple animal studies show sizable reductions in disease severity and marked survival benefits. That is real, encouraging science. But it has translated to only one documented human case so far, no controlled clinical trials have begun, and no product carries FDA approval. For now, stem cell therapy for NEC is a promising research direction moving carefully toward its first human trials — not a treatment available to sick newborns today.